Phase 1 Single dose pharmacokinetic study of CDRI compound 97/78, a novel antimalarial drug in healthy human volunteers
Latest Information Update: 09 Mar 2018
At a glance
- Drugs CDRI 9778 (Primary)
- Indications Malaria
- Focus Pharmacokinetics
- Sponsors Ipca Laboratories
- 26 Feb 2018 Status changed from recruiting to completed.
- 30 Mar 2016 New trial record